281 related articles for article (PubMed ID: 21690471)
1. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
Spunt SL; Grupp SA; Vik TA; Santana VM; Greenblatt DJ; Clancy J; Berkenblit A; Krygowski M; Ananthakrishnan R; Boni JP; Gilbertson RJ
J Clin Oncol; 2011 Jul; 29(21):2933-40. PubMed ID: 21690471
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
Becher OJ; Gilheeney SW; Khakoo Y; Lyden DC; Haque S; De Braganca KC; Kolesar JM; Huse JT; Modak S; Wexler LH; Kramer K; Spasojevic I; Dunkel IJ
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035748
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of everolimus in pediatric patients with refractory solid tumors.
Fouladi M; Laningham F; Wu J; O'Shaughnessy MA; Molina K; Broniscer A; Spunt SL; Luckett I; Stewart CF; Houghton PJ; Gilbertson RJ; Furman WL
J Clin Oncol; 2007 Oct; 25(30):4806-12. PubMed ID: 17947729
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
[TBL] [Abstract][Full Text] [Related]
8. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
[TBL] [Abstract][Full Text] [Related]
10. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Rangwala R; Chang YC; Hu J; Algazy KM; Evans TL; Fecher LA; Schuchter LM; Torigian DA; Panosian JT; Troxel AB; Tan KS; Heitjan DF; DeMichele AM; Vaughn DJ; Redlinger M; Alavi A; Kaiser J; Pontiggia L; Davis LE; O'Dwyer PJ; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1391-402. PubMed ID: 24991838
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Khawaja MR; Nick AM; Madhusudanannair V; Fu S; Hong D; McQuinn LM; Ng CS; Piha-Paul SA; Janku F; Subbiah V; Tsimberidou A; Karp D; Meric-Bernstam F; Lu KH; Naing A
Cancer Chemother Pharmacol; 2016 May; 77(5):973-7. PubMed ID: 27014780
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
Fouladi M; Perentesis JP; Wagner LM; Vinks AA; Reid JM; Ahern C; Thomas G; Mercer CA; Krueger DA; Houghton PJ; Doyle LA; Chen H; Weigel B; Blaney SM
Clin Cancer Res; 2015 Apr; 21(7):1558-65. PubMed ID: 25467181
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.
Gore L; Trippett TM; Katzenstein HM; Boklan J; Narendran A; Smith A; Macy ME; Rolla K; ; Narashimhan N; Squillace RM; Turner CD; Haluska FG; Nieder M
Clin Cancer Res; 2013 Jul; 19(13):3649-58. PubMed ID: 23659969
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
Mahadevan D; Chiorean EG; Harris WB; Von Hoff DD; Stejskal-Barnett A; Qi W; Anthony SP; Younger AE; Rensvold DM; Cordova F; Shelton CF; Becker MD; Garlich JR; Durden DL; Ramanathan RK
Eur J Cancer; 2012 Dec; 48(18):3319-27. PubMed ID: 22921184
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
Trivedi ND; Armstrong S; Wang H; Hartley M; Deeken J; Ruth He A; Subramaniam D; Melville H; Albanese C; Marshall JL; Hwang J; Pishvaian MJ
Cancer Med; 2021 Mar; 10(6):1944-1954. PubMed ID: 33638305
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of temsirolimus and metformin in advanced solid tumours.
MacKenzie MJ; Ernst S; Johnson C; Winquist E
Invest New Drugs; 2012 Apr; 30(2):647-52. PubMed ID: 20978924
[TBL] [Abstract][Full Text] [Related]
17. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
Diaz-Padilla I; Hirte H; Oza AM; Clarke BA; Cohen B; Reedjik M; Zhang T; Kamel-Reid S; Ivy SP; Hotte SJ; Razak AA; Chen EX; Brana I; Wizemann M; Wang L; Siu LL; Bedard PL
Invest New Drugs; 2013 Oct; 31(5):1182-91. PubMed ID: 23860641
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218.
Deyell RJ; Wu B; Rassekh SR; Tu D; Samson Y; Fleming A; Bouffet E; Sun X; Powers J; Seymour L; Baruchel S; Morgenstern DA
Pediatr Blood Cancer; 2019 Mar; 66(3):e27540. PubMed ID: 30393943
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.
Plimack ER; Tan T; Wong YN; von Mehren MM; Malizzia L; Roethke SK; Litwin S; Li T; Hudes GR; Haas NB
Oncologist; 2014 Apr; 19(4):354-5. PubMed ID: 24674872
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group.
Mizuno T; Fukuda T; Christians U; Perentesis JP; Fouladi M; Vinks AA
Br J Clin Pharmacol; 2017 May; 83(5):1097-1107. PubMed ID: 28000286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]